PURPOSE: The purpose of this study was to develop a Japanese version of hand-foot syndrome (HFS)-specific quality of life (QOL) questionnaire (HFS-14) to evaluate and monitor the QOL of patients with a possibility of HFS. METHODS: The original English version of HFS-14 was translated and slightly modified into Japanese, and the Japanese HFS-14 was administered to 187 patients receiving chemotherapy with high risk of developing HFS as outpatients in four institutions in Japan. Factor validity, internal consistency, correlation with the Skindex-16 and Dermatology Life Quality Index (DLQI) scores, known group validity, and test-retest reliability were analyzed for 105 patients who developed HFS. Next, we compared HFS-14 with DLQI and Skindex-16. RESULTS: Factor analysis confirmed the factor structure (one putative scale) of the Japanese HFS-14. Cronbach's alpha was over 0.90. The Japanese HFS-14 score was correlated with the Skindex-16 and DLQI score. Intra-class correlation coefficients were over 0.80. Patients with severe HFS reported significantly poorer HFS-14 score than those with mild HFS. The Skindex-16 and DLQI scores were also significantly different in patients with different Common Terminology Criteria for Adverse Events (CTCAE) grades, but with smaller effect sizes than those for the HFS-14 score. CONCLUSIONS: The Japanese HFS-14 provides a valid and reliable score for monitoring and evaluating HFS.
PURPOSE: The purpose of this study was to develop a Japanese version of hand-foot syndrome (HFS)-specific quality of life (QOL) questionnaire (HFS-14) to evaluate and monitor the QOL of patients with a possibility of HFS. METHODS: The original English version of HFS-14 was translated and slightly modified into Japanese, and the Japanese HFS-14 was administered to 187 patients receiving chemotherapy with high risk of developing HFS as outpatients in four institutions in Japan. Factor validity, internal consistency, correlation with the Skindex-16 and Dermatology Life Quality Index (DLQI) scores, known group validity, and test-retest reliability were analyzed for 105 patients who developed HFS. Next, we compared HFS-14 with DLQI and Skindex-16. RESULTS: Factor analysis confirmed the factor structure (one putative scale) of the Japanese HFS-14. Cronbach's alpha was over 0.90. The Japanese HFS-14 score was correlated with the Skindex-16 and DLQI score. Intra-class correlation coefficients were over 0.80. Patients with severe HFS reported significantly poorer HFS-14 score than those with mild HFS. The Skindex-16 and DLQI scores were also significantly different in patients with different Common Terminology Criteria for Adverse Events (CTCAE) grades, but with smaller effect sizes than those for the HFS-14 score. CONCLUSIONS: The Japanese HFS-14 provides a valid and reliable score for monitoring and evaluating HFS.
Authors: Vivian von Gruenigen; Heidi Frasure; Nancy Fusco; Robert DeBernardo; Elisa Eldermire; Susan Eaton; Steven Waggoner Journal: Cancer Date: 2010-10-15 Impact factor: 6.860
Authors: Chris Twelves; Alfred Wong; Marek P Nowacki; Markus Abt; Howard Burris; Alfredo Carrato; Jim Cassidy; Andrés Cervantes; Jan Fagerberg; Vassilis Georgoulias; Fares Husseini; Duncan Jodrell; Piotr Koralewski; Hendrik Kröning; Jean Maroun; Norbert Marschner; Joseph McKendrick; Marek Pawlicki; Riccardo Rosso; Johannes Schüller; Jean-François Seitz; Borut Stabuc; Jerzy Tujakowski; Guy Van Hazel; Jerzy Zaluski; Werner Scheithauer Journal: N Engl J Med Date: 2005-06-30 Impact factor: 91.245
Authors: Eun-Hyun Lee; Oran Kwon; Ki Baik Hahm; WonHee Kim; Jin Il Kim; Dae Young Cheung; Yoon Jae Kim; Jung Ho Kim; Jong-Jae Park; Moon Kyung Joo Journal: Health Qual Life Outcomes Date: 2016-02-17 Impact factor: 3.186